US · ESTA
Establishment Labs Holdings Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Alajuela
- Website
- establishmentlabs.com
Price · as of 2025-12-31
$70.23
Market cap 2.29B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $58.61 | -16.55% |
| Intrinsic Value(DCF) | $103.94 | +48% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $26.85 | $42.30 | $12,186.10 | $0.00 | $0.00 |
| 2019 | $19.08 | $34.71 | $1,241.65 | $0.00 | $0.00 |
| 2020 | $58.97 | $65.20 | $2.45 | $0.00 | $0.00 |
| 2021 | $56.25 | $49.15 | $214.54 | $0.00 | $0.00 |
| 2022 | $66.88 | $42.60 | $17.73 | $0.00 | $0.00 |
| 2023 | $50.41 | $32.26 | $5.19 | $0.00 | $0.00 |
| 2024 | $41.70 | $42.37 | $0.00 | $0.00 | $0.00 |
| 2025 | $76.10 | $58.61 | $0.01 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Establishment Labs Holdings Inc.'s (ESTA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $58.61
- Current price
- $70.23
- AI upside
- -16.55%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$103.94
+48% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ESTA | Establishment Labs Holdin… | $70.23 | 2.29B | -17% | +48% | — | — | -44.15 | 95.73 | 10.68 | -66.58 | — | 181.85 | 69.32% | -18.48% | -24.19% | -133.25% | -49.45% | -14.51% | 0.12 | -1.54 | 3.04 | 1.86 | 2.22 | -4267.00% | 2714.00% | -2314.00% | -2.53% | -0.62 | -82.02% | 0.00% | 0.00% | 9.21% | -55.92 | -38.31 | 10.34 | 4.85 |
| AHCO | AdaptHealth Corp. | $9.15 | 1.24B | +239% | -53% | — | — | -19.73 | 0.86 | 0.40 | 2.75 | — | -1.18 | 17.52% | 5.74% | -2.18% | -4.27% | 7.18% | -1.50% | 0.12 | 1.76 | 1.02 | 0.67 | 0.16 | -18525.00% | -49.00% | -696.00% | 16.84% | 0.84 | 8.45% | 0.00% | 0.00% | 148.90% | 7.43 | 6.31 | 0.43 | 0.97 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| CNMD | CONMED Corporation | $46.00 | 1.42B | +64% | -60% | -94% | -57% | 30.20 | 1.38 | 1.03 | 12.53 | — | -3.99 | 53.87% | 9.47% | 3.42% | 4.72% | 4.69% | 2.03% | 0.81 | 4.19 | 2.14 | 0.92 | 4.49 | -6455.00% | 518.00% | -195.00% | 10.62% | 0.54 | 8.22% | 1.74% | 52.60% | 7.88% | 17.02 | 14.68 | 1.61 | 1.97 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| SSII | SS Innovations Internatio… | $4.76 | 921.64M | +1,445% | +6,162% | — | — | -85.61 | 121.83 | 79.40 | -93.41 | — | 121.83 | 40.93% | -91.90% | -92.74% | -138.00% | -81.31% | -56.44% | 1.35 | -19.50 | 1.29 | 0.36 | -1.00 | -3750.00% | 25120.00% | -3573.00% | -0.62% | -0.45 | -43.55% | 0.00% | 0.00% | 0.00% | -87.33 | -163.04 | 80.26 | 31.74 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| TDOC | Teladoc Health, Inc. | $5.26 | 933.51M | +398% | -42% | -89% | — | -4.54 | 0.66 | 0.36 | 7.86 | — | -4.67 | 69.50% | -10.39% | -7.92% | -13.93% | -13.11% | -6.28% | 0.74 | -13.34 | 2.77 | 2.41 | 1.68 | -8058.00% | -154.00% | 91.00% | 31.39% | 0.73 | 16.74% | 0.00% | 0.00% | 4.21% | -4.40 | 4.05 | 0.46 | -6.80 |
| UFPT | UFP Technologies, Inc. | $210.58 | 1.62B | -43% | +6% | -65% | +13% | 23.04 | 3.71 | 2.61 | 14.60 | 146.78 | 18.38 | 28.27% | 15.32% | 11.33% | 17.82% | 14.23% | 10.64% | 0.32 | 9.42 | 1.19 | 0.65 | 0.99 | 1570.00% | 1950.00% | 3871.00% | 5.02% | 0.58 | 14.70% | 0.00% | 0.00% | 4.92% | 18.29 | 21.39 | 2.80 | 5.53 |
| ZYME | Zymeworks Inc. | $23.29 | 1.74B | +9% | -79% | — | — | -7.42 | 2.69 | 11.93 | -6.47 | — | 2.83 | 100.00% | -179.69% | -160.80% | -30.54% | -110.26% | -23.51% | 0.05 | — | 3.40 | 3.19 | 0.44 | -581.00% | 38.00% | -757.00% | -12.43% | -1.25 | -90.96% | 0.00% | 0.00% | 3.30% | -5.13 | -6.21 | 9.21 | 1.62 |
About Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
- CEO
- Fillipo Peter Caldini
- Employees
- 1.03K
- Beta
- 0.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($103.94 ÷ $70.23) − 1 = +48% (DCF, example).